Cipla stock jumps to all-time high; Nuvama raises target price, sees 18% upside

Cipla is aiming to transition from a pure-play pharma company to an integrated health player, per analysts.

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *